{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":7,"sponsored":0,"items":[{"id":"n_4kn2ov4xwveuy6xk224q","seq":1334098,"kind":"article","title":"Health: AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination","url":"https://www.gdnonline.com/Details/1408377/AstraZeneca,-Daiichi-Sankyo-partner-with-Summit-to-test-cancer-drug-combination","published":"2026-10-02T11:53:15Z","seen":"2026-10-02T11:53:15Z","lang":"en","source":{"id":"gdnonline.com","name":"gdnonline.com","domain":"gdnonline.com"},"via":"gdelt-gkg-english","topics":["health","economy"],"entities":[{"id":"Q731938","name":"AstraZeneca","type":"org"},{"id":"Q669441","name":"Daiichi Sankyo","type":"org"},{"id":"Q207326","name":"summit","type":"org"}],"story":"st_d37ka6wke3x4h4tdoaka","category":"health","category_p":0.63,"sentiment":"positive","tone":-0.1,"political":0.1},{"id":"n_uqvolwugtjpkbmdyoppa","seq":1311245,"kind":"article","title":"AstraZeneca, Daiichi Sankyo, Summit to Test Drug Combination","url":"https://www.miragenews.com/astrazeneca-daiichi-sankyo-summit-to-test-drug-1754306","published":"2026-10-02T09:38:11Z","seen":"2026-10-02T09:38:11Z","lang":"en","source":{"id":"miragenews.com","name":"miragenews.com","domain":"miragenews.com"},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q731938","name":"AstraZeneca","type":"org"},{"id":"Q669441","name":"Daiichi Sankyo","type":"org"},{"id":"Q207326","name":"summit","type":"org"}],"story":"st_d37ka6wke3x4h4tdoaka","category":"health","category_p":0.33,"sentiment":"neutral","tone":0.15,"political":0.11},{"id":"n_d37ka6wke3x4h4tdoaka","seq":1293969,"kind":"article","title":"AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combo","url":"https://www.sowetan.co.za/news/world/2026-10-02-astrazeneca-daiichi-sankyo-partner-with-summit-to-test-cancer-drug-combo","summary":"AstraZeneca, Daiichi Sankyo, and Summit Therapeutics will jointly test cancer drugs Datroway and ivonescimab in a Phase III trial for triple-negative breast cancer","published":"2026-10-02T07:54:14Z","seen":"2026-10-02T08:16:31Z","lang":"en","country":"ZA","source":{"id":"kite-sowetan-co-za-f35324","name":"sowetan.co.za","domain":"sowetan.co.za"},"via":"kite-sowetan-co-za-f35324","topics":["sci-tech"],"authors":["Reuters Agency"],"entities":[{"id":"Q731938","name":"AstraZeneca","type":"org"},{"id":"Q669441","name":"Daiichi Sankyo","type":"org"},{"id":"Q207326","name":"summit","type":"org"}],"image":"https://www.sowetan.co.za/resizer/v2/WGEBOEAIFZC5BPAFM7I5LCWTA4.JPG?auth=97408645fec2e2cbc8b39ca8980198215e08218f94b4e505b9ff05631abeb2a8&height=350&smart=true&width=800","story":"st_d37ka6wke3x4h4tdoaka","category":"health","category_p":0.5,"sentiment":"positive","tone":0.3,"political":0.13},{"id":"n_uy3l4b34lsz2gvtctc4q","seq":429351,"kind":"article","title":"NTK Appeals Tokyo Court's Dismissal of ¥203.3bn Damages Claim Against Daiichi Sankyo","url":"https://tokyobrief.com/articles/daiichi-sankyo-ntk-appeal-tokyo-high-court","summary":"Northern TK Venture has appealed to the Tokyo High Court after the district court threw out its entire ¥203.3 billion damages claim against Daiichi Sankyo over a blocked Fortis Healthcare tender offer, and the pharma company now says the earnings impact is under review rather than nil.","published":"2026-09-28T12:01:07Z","seen":"2026-09-28T12:52:19Z","lang":"ja","country":"JP","source":{"id":"kite-tokyobrief-com-a5667e","name":"tokyobrief.com","domain":"tokyobrief.com","outlet":{"wikidata":"Q141513445","name":"Tokyo Brief","type":"other","designations":["newsletter"]}},"via":"kite-tokyobrief-com-a5667e","entities":[{"id":"Q837048","name":"Ngau Tau Kok","type":"org"},{"id":"Q669441","name":"Daiichi Sankyo","type":"org"}],"image":"https://tokyobrief.com/media/tokyo-brief-2026-09-28-daiichi-sankyo-ntk-appeal-tokyo-high-court-de62c709e58e48dc69a7addeb36f6630c0ffafe43a7e68dd182285110e37cdf2.png?v=card","story":"st_uy3l4b34lsz2gvtctc4q","category":"economy-business","category_p":0.37,"sentiment":"negative","tone":-0.6,"political":0.36},{"id":"n_tslsazy4xjr2s67snw3a","seq":401458,"kind":"article","title":"Daiichi Sankyo, MSD withdraw cancer drug application","url":"https://www.pharmaceutical-business-review.com/news/daiichi-sankyo-msd-cancer-application","published":"2026-09-28T10:40:44Z","seen":"2026-09-28T10:40:44Z","lang":"en","source":{"id":"pharmaceutical-business-review.com","name":"pharmaceutical-business-review.com","domain":"pharmaceutical-business-review.com"},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q669441","name":"Daiichi Sankyo","type":"org"},{"id":"Q247489","name":"Merck & Co.","type":"org"}],"story":"st_tslsazy4xjr2s67snw3a","category":"health","category_p":0.46,"sentiment":"neutral","tone":-0.25,"political":0.39},{"id":"n_uto6y5rjn3jgzt76tmoq","seq":389026,"kind":"article","title":"第一三共、米国で肺がん治療薬の迅速承認の申請取り下げ","title_en":"Daiichi Sankyo withdraws application for rapid approval of lung cancer treatment drug in the US","url":"https://www.nikkei.com/article/DGXZQOUC280I50Y6A920C2000000","published":"2026-09-28T06:32:23Z","seen":"2026-09-28T09:33:26Z","lang":"ja","country":"JP","source":{"id":"kite-assets-wor-jp-8be20c","name":"assets.wor.jp","domain":"assets.wor.jp"},"via":"kite-assets-wor-jp-8be20c","entities":[{"id":"Q669441","name":"Daiichi Sankyo","type":"org"}],"story":"st_uto6y5rjn3jgzt76tmoq","category":"health","category_p":0.51,"category2":"politics","sentiment":"negative","tone":-0.47,"political":0.63},{"id":"n_7lb5b7uhigojukyklulq","seq":321847,"kind":"article","title":"머크·다이이찌산쿄, 폐암 신약 'Ifinatamab Deruxtecan' FDA 허가 신청 철회","title_en":"Merck and Daiichi Sankyo withdraw FDA approval application for new lung cancer drug 'Ifinatamab Deruxtecan'","url":"https://www.pharmnews.com/news/articleView.html?idxno=306528","summary":"[팜뉴스=우정민 기자] 머크와 다이이찌산쿄가 폐암 치료제의 미국 허가 신청을 철회했다. 25일(현지시간) 양사는 백금 기반 화학요법 치료 후 병이 진행된 진전기 소세포폐암 환자용 항체-약물 접합체(ADC) \\'Ifinatamab Deruxtecan, I-DXd\\'의 생물학적 제제 품목허가를 취소한다고 밝혔다.당초 2026년 4월 미국 식품의약국(FDA)으로부터 우선심사 대상으로 지정돼 오는 10월 10일 최종 승인 여부 결정을 앞두고 있었으나, 임상 2상 데이터만으로는 신속 승인 기준을 충족하기 어렵다는 당국의 의견을 반영한 결정이다.","published":"2026-09-28T00:11:46Z","seen":"2026-09-28T01:33:18Z","lang":"ko","source":{"id":"kite-cdn-pharmnews-com-3e2457","name":"cdn.pharmnews.com","domain":"cdn.pharmnews.com"},"via":"kite-cdn-pharmnews-com-3e2457","topics":["medicine","산업"],"authors":["우정민 기자"],"entities":[{"id":"Q96472579","name":"Merck","type":"org"},{"id":"Q669441","name":"Daiichi Sankyo","type":"org"},{"id":"Q123582114","name":"ifinatamab deruxtecan","type":"other"}],"story":"st_7lb5b7uhigojukyklulq","category":"health","category_p":0.4,"category2":"politics","sentiment":"neutral","tone":-0.35,"political":0.52}]}